Advertisement

An Overview of Clinical Trials in the Treatment of Resectable Hepatocellular Carcinoma

Published:November 03, 2022DOI:https://doi.org/10.1016/j.soc.2022.07.008

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sung H.
        • Ferlay J.
        • Siegel R.L.
        • et al.
        Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2021; 71: 209-249
        • Akateh C.
        • Black S.M.
        • Conteh L.
        • et al.
        Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.
        World J Gastroenterol. 2019; 25: 3704-3721
        • Yopp A.C.
        • Mansour J.C.
        • Beg M.S.
        • et al.
        Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome.
        Ann Surg Oncol. 2014; 21: 1287-1295
        • Mazzaferro V.
        • Regalia E.
        • Doci R.
        • et al.
        Liver Transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.
        N Engl J Med. 1996; 334: 693-699
        • Pompili M.
        • Mirante V.G.
        • Rondinara G.
        • et al.
        Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence.
        Liver Transpl. 2005; 11: 1117-1126
        • Marubashi S.
        • Gotoh K.
        • Akita H.
        • et al.
        Anatomical versus non-anatomical resection for hepatocellular carcinoma.
        Br J Surg. 2015; 102: 776-784
        • Zhu H.
        • Xing H.
        • Yu B.
        • et al.
        Long-term survival and recurrence after curative resection for hepatocellular carcinoma in patients with chronic hepatitis C virus infection: a multicenter observational study from China.
        HPB (Oxford). 2020; 22: 1793-1802
        • Li T.
        • Qin L.X.
        • Gong X.
        • et al.
        Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence of female patients after curative resection of hepatocellular carcinoma.
        Surgery. 2014; 156: 651-660
        • Imamura H.
        • Matsuyama Y.
        • Tanaka E.
        • et al.
        Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.
        J Hepatol. 2003; 38: 200-207
        • Makuuchi M.
        • Hasegawa H.
        • Yamazaki S.
        Ultrasonically guided subsegmentectomy.
        Surg Gynecol Obstet. 1985; 161: 346-350
        • Aoki T.
        • Murakami M.
        • Yasuda D.
        • et al.
        Intraoperative fluorescent imaging using indocyanine green for liver mapping and cholangiography.
        J Hepatobiliary Pancreat Sci. 2010; 17: 590-594
        • Couinaud C.
        A simplified method for controlled left hepatectomy.
        Surgery. 1985; 97: 358-361
        • Takasaki K.
        Glissonean pedicle transection method for hepatic resection: a new concept of liver segmentation.
        J Hepato-Biliary-Pancreatic Surg. 1998; 5: 286-291
        • Nevarez N.M.
        • Yopp A.C.
        Anatomic vs. non-anatomic liver resection for hepatocellular carcinoma: standard of care or unfilled promises?.
        Hepatoma Res. 2021; https://doi.org/10.20517/2394-5079.2021.66
        • Zhou Y.
        • Xu D.
        • Wu L.
        • et al.
        Meta-analysis of anatomic resection versus nonanatomic resection for hepatocellular carcinoma.
        Langenbecks Arch Surg. 2011; 396: 1109-1117
        • Ye J.Z.
        • Miao Z.G.
        • Wu F.X.
        • et al.
        Recurrence after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis.
        Asian Pac J Cancer Prev. 2012; 13: 1771-1777
        • Cucchetti A.
        • Cescon M.
        • Ercolani G.
        • et al.
        A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma.
        Ann Surg Oncol. 2012; 19: 3697-3705
        • Feng X.
        • Su Y.
        • Zheng S.
        • et al.
        A double blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence.
        HPB (Oxford). 2017; 19: 667-674
        • Huang X.
        • Lu S.
        A Meta-analysis comparing the effect of anatomical resection vs. non-anatomical resection on the long-term outcomes for patients undergoing hepatic resection for hepatocellular carcinoma.
        HPB (Oxford). 2017; 19: 843-849
        • Tan Y.
        • Zhang W.
        • Jiang L.
        • et al.
        Efficacy and safety of anatomic resection versus nonanatomic resection in patients with hepatocellular carcinoma: A systemic review and meta-analysis.
        PLoS One. 2017; 12: e0186930
        • Moris D.
        • Tsilimigras D.I.
        • Kostakis I.D.
        • et al.
        Anatomic versus non-anatomic resection for hepatocellular carcinoma: a systematic review and meta-analysis.
        Eur J Surg Oncol. 2018; 44: 927-938
        • Famularo S.
        • Ceresoli M.
        • Giani A.
        • et al.
        Is it just a matter of surgical extension to achieve the cure of hepatocarcinoma? A meta-analysis of propensity-matched and randomized studies for anatomic versus parenchyma-sparing liver resection.
        J Gastrointest Surg. 2021; 25: 94-103
        • Sun Z.
        • Li Z.
        • Shi X.L.
        • et al.
        Anatomic versus non-anatomic resection of hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis.
        Asian J Surg. 2021; 44: 1143-1150
        • Ozawa K.
        Hepatic function and liver resection.
        J Gastroenterol Hepatol. 1990; 5: 296-309
        • Lai E.C.S.
        • Fan S.-T.F.
        • Lo C.-M.
        • et al.
        Anterior approach for difficult major right hepatectomy.
        World J Surg. 1996; 20: 314-318
        • Belghiti J.
        • Guevara O.A.
        • Noun R.
        • et al.
        Liver handing maneuver: a safe approach to right hepatectomy liver mobilization.
        J Am Coll Surg. 2001; 193: 109-111
        • Liu C.L.
        • Fan S.T.
        • Cheung S.T.
        • et al.
        Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study.
        Ann Surg. 2006; 244: 194-203
        • Beppu T.
        • Imai K.
        • Okuda K.
        • et al.
        Anterior approach for right hepatectomy with hanging maneuver for hepatocellular carcinoma: a multi-institutional propensity score-matching study.
        J Hepatobiliary Pancreat Sci. 2017; 24: 127-136
        • Chan K.M.
        • Wang Y.C.
        • Wu T.H.
        • et al.
        The preference for anterior approach major hepatectomy: experience over 3 decades and a propensity score-matching analysis in right hepatectomy for hepatocellular carcinoma.
        Medicine (Baltimore). 2015; 94: e1385
        • Otsubo T.
        • Takasaki K.
        • Yamamoto M.
        • et al.
        Bleeding during hepatectomy can be reduced by clamping the inferior vena cava below the liver.
        Surgery. 2004; 135: 67-73
        • Rahbari N.N.
        • Koch M.
        • Zimmermann J.B.
        • et al.
        Infrahepatic inferior vena cava clamping for reduction of central venous pressure and blood loss during hepatic resection: a randomized controlled trial.
        Ann Surg. 2011; 253: 1102-1110
        • Zhou Y.M.
        • Sui C.J.
        • Zhang X.F.
        • et al.
        Anterior approach combined with infrahepatic inferior vena cava clamping right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled trial.
        Medicine (Baltimore). 2016; 95: e4159
        • Capussotti L.
        • Ferrero A.
        • Russolillo N.
        • et al.
        Routine anterior approach during right hepatectomy: results of a prospective randomised controlled trial.
        J Gastrointest Surg. 2012; 16: 1324-1332
        • Chen L.T.
        • Chen M.F.
        • Li L.A.
        • et al.
        Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.
        Ann Surg. 2012; 255: 8-17
        • Kubo S.
        • Nishiguchi S.
        • Hirohashi K.
        • et al.
        Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy.
        Br J Surg. 2002; 89: 418-422
        • Lo C.M.
        • Liu C.L.
        • Chan S.C.
        • et al.
        A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.
        Ann Surg. 2007; 245: 831-842
        • Kubo S.
        • Nishiguchi S.
        • Hirohashi K.
        • et al.
        Effects of Long-Term Postoperative Interferon-Alpha Therapy on Intrahepatic Recurrence after Resection of Hepatitis C Virus–Related Hepatocellular Carcinoma.
        Ann Intern Med. 2001; 134: 963-967
        • Ikeda K.
        • Arase Y.
        • Saitoh S.
        • et al.
        Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer.
        Hepatology. 2000; 32: 228-232
        • Huang G.
        • Lau W.Y.
        • Wang Z.G.
        • et al.
        Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.
        Ann Surg. 2015; 261: 56-66
        • Huang G.
        • Li P.P.
        • Lau W.Y.
        • et al.
        Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial.
        Ann Surg. 2018; 268: 943-954
        • Yin J.
        • LI N.
        • Han Y.
        • et al.
        Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus– related hepatocellular carcinoma: a two-stage longitudinal clinical study.
        J Clin Oncol. 2013; 31: 3647-3655
        • Chen K.
        • Xia Y.
        • Wang H.
        • et al.
        Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial.
        PLoS One. 2013; 8: e57397
        • Llovet J.M.
        • Ricci S.
        • Mazzaferro V.
        • et al.
        Sorafenib in advanced hepatocellular carcinoma.
        N Engl J Med. 2008; 359: 378-390
        • Bruix J.
        • Takayama T.
        • Mazzaferro V.
        • et al.
        Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
        Lancet Oncol. 2015; 16: 1344-1354
        • Fujiwara H.
        • Terashima M.
        • Irinoda T.
        • et al.
        Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR.
        Jpn J Cancer Res. 2002; 93: 1342-1350
        • Ishizuka M.
        • Kubota K.
        • Nemoto T.
        • et al.
        Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial.
        Asian J Surg. 2016; 39: 149-154
        • Zhou J.
        • Tang Z.
        • Wu Z.
        Capecitabine inhibition of recurrence and metastasis after liver cancer resection in nude mice.
        Chin Med J. 2001; 39: 199-201
        • Hoff P.M.
        • Ansari R.
        • Batist G.
        • et al.
        Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
        J Clin Oncol. 2001; 19: 2282-2292
        • Zhou J.
        • Tang Z.-Y.
        • Fan J.
        • et al.
        Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
        Clin Cancer Res. 2003; 9: 6030-6037
        • Xia Y.
        • Qiu Y.
        • Li J.
        • et al.
        Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
        Ann Surg Oncol. 2010; 17: 3137-3144
        • Finn R.S.
        • Qin S.
        • Ikeda M.
        • et al.
        Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
        N Engl J Med. 2020; 382: 1894-1905
        • Finn R.S.
        • Ryoo B.Y.
        • Merle P.
        • et al.
        Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial.
        J Clin Oncol. 2020; 38: 193-202
        • Zhu A.X.
        • Finn R.S.
        • Edeline J.
        • et al.
        Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
        Lancet Oncol. 2018; 19: 940-952
        • Yau T.
        • Kang Y.K.
        • Kim T.Y.
        • et al.
        Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkMate 040 randomized clinical trial.
        JAMA Oncol. 2020; 6: e204564
        • Yau T.
        • Park J.-W.
        • Finn R.S.
        • et al.
        Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
        Lancet Oncol. 2022; 23: 77-90
        • El-Khoueiry A.B.
        • Sangro B.
        • Yau T.
        • et al.
        Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
        Lancet. 2017; 389: 2492-2502
        • Kudo M.
        • Ueshima K.
        • Nakahira S.
        • et al.
        Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.
        J Clin Oncol. 2022; 40: 416
        • Hack S.P.
        • Spahn J.
        • Chen M.
        • et al.
        IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.
        Future Oncol. 2020; 16: 975-989
        • Jimenez Exposito M.J.
        • Akce M.
        • Montero Alvarez J.L.
        • et al.
        CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation.
        Ann Oncol. 2018; 29: viii267-viii268https://doi.org/10.1093/annonc/mdy282.166
        • Takayama T.
        • Sekine T.
        • Makuuchi M.
        • et al.
        Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.
        Lancet. 2000; 356: 802-807
        • Hui D.
        • Qiang L.
        • Jian W.
        • et al.
        A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.
        Dig Liver Dis. 2009; 41: 36-41
        • Lee J.H.
        • Lee J.H.
        • Lim Y.S.
        • et al.
        Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
        Gastroenterology. 2015; 148: 1383-13891 e6
        • Yoo H.S.Y.
        • Lee J.T.
        • Kim K.W.
        • et al.
        Nodular hepatocellular carcinoma: treatment with subsegmental intraarterial injection of iodine z3 1-labeled iodized Oil.
        Cancer. 1991; 68: 1878-1884
        • Yumoto Y.
        • Jinno K.
        • Inatsuki S.
        • et al.
        Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution.
        Cancer Chemother Pharmcol. 1992; 31: S128-S136
        • Mantravadi R.V.P.
        • Spigos D.C.
        • Tan W.S.
        • et al.
        lntraarterial Yttrium 90 in the treatment of hepatic malignancy.
        Radiology. 1982; 142: 783-786
        • Partensky C.
        • Sassolas G.
        • Henry L.
        • et al.
        Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma.
        Arch Surg. 2000; 135: 1298-1300
        • Lau W.Y.
        • Leung T.W.T.
        • Ho S.K.W.
        • et al.
        Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial.
        The Lancet. 1999; 353: 797-801https://doi.org/10.1016/s0140-6736(98)06475-7
        • Lau W.Y.
        • Lai E.C.
        • Leung T.W.
        • et al.
        Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival.
        Ann Surg. 2008; 247: 43-48
        • Chung A.Y.
        • Ooi L.L.
        • Machin D.
        • et al.
        Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial.
        World J Surg. 2013; 37: 1356-1361
        • Dumortier J.
        • Decullier E.
        • Hilleret M.N.
        • et al.
        Adjuvant Intraarterial Lipiodol or (1)(3)(1)I-Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial.
        J Nucl Med. 2014; 55: 877-883
        • Zhong C.
        • Guo R.P.
        • Li J.Q.
        • et al.
        A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for stage III A hepatocellular carcinoma.
        J Cancer Res Clin Oncol. 2009; 135: 1437-1445
        • (UICC) IUAC
        TNM classification of malignant tumors.
        6th edition. Wiley, Hoboken, NJ2002
        • Wang Z.
        • Ren Z.
        • Chen Y.
        • et al.
        Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study.
        Clin Cancer Res. 2018; 24: 2074-2081
        • Hirokawa F.
        • Komeda K.
        • Taniguchi K.
        • et al.
        Is Postoperative adjuvant transcatheter arterial infusion therapy effective for patients with hepatocellular carcinoma who underwent hepatectomy? A prospective randomized controlled trial.
        Ann Surg Oncol. 2020; 27: 4143-4152
        • Li J.
        • Xing J.
        • Yang Y.
        • et al.
        Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial.
        Lancet Gastroenterol Hepatol. 2020; 5: 548-560
        • Li S.
        • Mei J.
        • Wang Q.
        • et al.
        Postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: a preliminary report of a phase III, randomized controlled clinical trial.
        Ann Surg Oncol. 2020; 27: 5183-5190
        • Yu W.
        • Wang W.
        • Rong W.
        • et al.
        Adjuvant radiotherapy in centrally located hepatocellular carcinomas after hepatectomy with narrow margin (<1 cm): a prospective randomized study.
        J Am Coll Surg. 2014; 218: 381-392
        • Sun J.
        • Yang L.
        • Shi J.
        • et al.
        Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: An open-label randomized controlled trial.
        Radiother Oncol. 2019; 140: 20-25
        • Zhou W.P.
        • Lai E.C.
        • Li A.J.
        • et al.
        A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma.
        Ann Surg. 2009; 249: 195-202
        • Pinato D.J.
        • Cortellini A.
        • Sukumaran A.
        • et al.
        PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
        BMC Cancer. 2021; 21: 301
        • Kaseb A.O.
        • Pestana R.C.
        • Vence L.M.
        • et al.
        Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
        J Clin Oncol. 2019; 37: 185
        • Wei X.
        • Jiang Y.
        • Zhang X.
        • et al.
        Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study.
        J Clin Oncol. 2019; 37: 2141-2151